The double-blind, multicenter, placebo-controlled, randomized study is designed to assess the safety, tolerability, and efficacy of AVP-923.
The primary efficacy endpoint will be measured based on the Numeric Pain Rating Scale as recorded in patient diaries.
Secondary assessments include measures of fatigue, impact of MS on daily life, sleep quality, cognition and depression.
Avanir research and development senior vice president Joao Siffert said in addition, they look forward to explore the potential of AVP-923 across a broad range of other CNS disorders.